Shots:

• OliX to receive $2.27M upfront- clinical milestones and royalties on sales of product. Thea to get license rights to develop & commercialize OLX301A in EU- Middle East and Africa (Ex- the US & Asia)
• The focus of the agreement is to develop therapies based on OliX’s RNAi technology with the expansion of Thea’s Ophthalmology portfolio in retinal vascular diseases
• OliX’s OLX301A is a novel therapy based on RNAi technology used for the development of ocular therapeutics and is currently evaluated in P-I trial for dry and wet age-related macular degeneration

Ref: Olix | Image: Twitter